EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients

Nidhi Dhariwal, Shyam Srinivasan

American Journal of Blood Research · 2026

DOI: 10.62347/vckt6128 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Blood Research, 2026. Verfasst von Nidhi Dhariwal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre New Chandigarh, Punjab, India. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Venetoclaxchemotherapyintolerancelow-intensitypediatric AML

Autor:innen und Institutionen

  • Division of Pediatric Oncology, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre New Chandigarh, Punjab, India.
  • Division of Pediatric Oncology, Department of Medical Oncology, Tata Memorial Hospital Mumbai, Maharashtra, India.

Zitieren

APA

Dhariwal, N., & Srinivasan, S. (2026). Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. American Journal of Blood Research. https://doi.org/10.62347/vckt6128

Vancouver

Dhariwal N, Srinivasan S. Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. American Journal of Blood Research. 2026. doi:10.62347/vckt6128

BibTeX
@article{Dhariwal2026,
  author = {Dhariwal, Nidhi and Srinivasan, Shyam},
  title = {Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients},
  journal = {American Journal of Blood Research},
  year = {2026},
  doi = {10.62347/vckt6128}
}
Kostenlos starten →